ScoreWhy is Editas Medicine, Inc. ?
1
Poor long term growth as Net Sales has grown by an annual rate of -12.73% and Operating profit at -2.18% over the last 5 years
2
With a growth in Net Sales of 228%, the company declared Very Positive results in Sep 25
- The company has declared positive results in Jan 70 after 4 consecutive negative quarters
- NET SALES(HY) At USD 11.12 MM has Grown at 1,837.46%
- DEBT-EQUITY RATIO (HY) Lowest at -646.15 %
- RAW MATERIAL COST(Y) Fallen by -103.55% (YoY)
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 61.87%, its profits have risen by 42.7%
4
High Institutional Holdings at 74.46%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Market Beating Performance
- The stock has generated a return of 61.87% in the last 1 year, much higher than market (S&P 500) returns of 13.68%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Editas Medicine, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Editas Medicine, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Editas Medicine, Inc.
66.91%
-0.59
97.70%
S&P 500
13.68%
0.71
19.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-12.73%
EBIT Growth (5y)
-2.18%
EBIT to Interest (avg)
-167.40
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-3.33
Sales to Capital Employed (avg)
0.29
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
74.46%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
18.48
EV to EBIT
-1.24
EV to EBITDA
-1.30
EV to Capital Employed
-1.70
EV to Sales
3.19
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-896.96%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend21What is working for the Company
NET SALES(HY)
At USD 11.12 MM has Grown at 1,837.46%
DEBT-EQUITY RATIO
(HY)
Lowest at -646.15 %
RAW MATERIAL COST(Y)
Fallen by -103.55% (YoY
PRE-TAX PROFIT(Q)
Highest at USD -25.12 MM
NET PROFIT(Q)
Highest at USD -25.12 MM
EPS(Q)
Highest at USD -0.28
-11What is not working for the Company
ROCE(HY)
Lowest at -211.37%
CASH AND EQV(HY)
Lowest at USD 344.15 MM
DEBTORS TURNOVER RATIO(HY)
Lowest at 11.24 times
INTEREST(Q)
Highest at USD 2.4 MM
Here's what is working for Editas Medicine, Inc.
Net Sales
At USD 11.12 MM has Grown at 1,837.46%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Debt-Equity Ratio
Lowest at -646.15 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Pre-Tax Profit
Highest at USD -25.12 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -25.12 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD -0.28
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Raw Material Cost
Fallen by -103.55% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Editas Medicine, Inc.
Interest
At USD 2.4 MM has Grown at 18.76%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Interest
Highest at USD 2.4 MM
in the last five periods and Increased by 18.76% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Cash and Eqv
Lowest at USD 344.15 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debtors Turnover Ratio
Lowest at 11.24 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
